Injunction

Bound2B successfully obtains preliminary injunction against Xolution Germany GmbH and its re-sealable XO closing device on beverage cans

Retrieved on: 
Thursday, March 21, 2024
Federal Patent Court, District court, Injunction, XO, Judgement, European Patent Convention, Patent, EP, Court

RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.  The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.

Key Points: 
  • in particular its XO closing device, in Germany
    RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.
  • The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.
  • In 2020, Bound2B initiated patent infringement proceedings before the District Court of Düsseldorf based on EP 930 against Xolution GmbH, who manufactured, advertised, and delivered the XO closing device.
  • In order to prevent further offering and selling of the XO closing device in Germany, Bound2B filed for urgent proceedings and asked the Düsseldorf Court to immediately issue a preliminary injunction against Xolution Germany GmbH as well as its Managing Director, Mr. von Rettberg.

Bound2B successfully obtains preliminary injunction against Xolution Germany GmbH and its re-sealable XO closing device on beverage cans

Retrieved on: 
Thursday, March 21, 2024
Federal Patent Court, District court, Injunction, XO, Judgement, European Patent Convention, Patent, EP, Court

RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.  The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.

Key Points: 
  • in particular its XO closing device, in Germany
    RHENEN, Netherlands, March 21, 2024 /PRNewswire/ -- Bound2B B.V., the creator and owner of several resealable beverage can patents and technologies in Europe and the US, today announced that it has successfully obtained a preliminary injunction against Xolution Germany GmbH.
  • The decision was issued by the District Court of Düsseldorf, Germany, and follows infringement proceedings filed by Bound2B against Xolution GmbH.
  • In 2020, Bound2B initiated patent infringement proceedings before the District Court of Düsseldorf based on EP 930 against Xolution GmbH, who manufactured, advertised, and delivered the XO closing device.
  • In order to prevent further offering and selling of the XO closing device in Germany, Bound2B filed for urgent proceedings and asked the Düsseldorf Court to immediately issue a preliminary injunction against Xolution Germany GmbH as well as its Managing Director, Mr. von Rettberg.

AHIMA Announces 2024 Board President/Chair, New Board Members

Retrieved on: 
Thursday, January 18, 2024
MCS, Lakeland Community College, RHIT, CCS, University, Risk, Journal, Doctor of Philosophy, Cuyahoga Community College, Information management, Community college, Commission, HIM, CHPS, Coppin, UCLA Health, AHIMA, Rehabilitation, Health information management, Coppin State University, MBA, Accreditation, MSML, Informatics, Injunction, CDI, Cuyahoga, Texas Health Resources, Advisory board, FACEP, Management

CHICAGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Members of the American Health Information Management Association (AHIMA) elected Mona Calhoun, PhD, MS, Med, RHIA, FAHIMA, as president/chair of the 2024 AHIMA Board of Directors.

Key Points: 
  • CHICAGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Members of the American Health Information Management Association (AHIMA) elected Mona Calhoun, PhD, MS, Med, RHIA, FAHIMA, as president/chair of the 2024 AHIMA Board of Directors.
  • "I look forward to working closely with our dynamic, visionary, and committed Board members in 2024," expressed Dr. Klauer.
  • In addition to Calhoun's appointment, AHIMA members selected a president/chair-elect and three new members of the Board of Directors (each of whom will serve a three-year term).
  • Additionally, she helped author the AHIMA CDI Toolkit, participated in the AHIMA Future of the House Taskforce and the AHIMA Envisioning Collaborative, and is an AHIMA Mentor.

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

Retrieved on: 
Wednesday, August 30, 2023
1836 U.S. Patent Office fire, Patent, Orange, Teva, Justice, United States Department of Justice, Naltrexone, Federal Trade Commission, ALKS, Food and Drug Administration, Orange Book, Injunction, VIVITROL, District court, Alkermes, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Court, Douglas v. U.S. District Court ex rel Talk America, Generic drug

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension). Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No. 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.

Key Points: 
  • DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension).
  • Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No.
  • 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.
  • The company and Teva will submit the settlement agreement for review to the United States Federal Trade Commission and the United States Department of Justice.

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

Retrieved on: 
Wednesday, August 30, 2023
1836 U.S. Patent Office fire, Patent, Orange, Teva, Justice, United States Department of Justice, Naltrexone, Federal Trade Commission, ALKS, Food and Drug Administration, Orange Book, Injunction, VIVITROL, District court, Alkermes, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Court, Douglas v. U.S. District Court ex rel Talk America, Generic drug

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension). Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No. 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.

Key Points: 
  • DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension).
  • Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No.
  • 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.
  • The company and Teva will submit the settlement agreement for review to the United States Federal Trade Commission and the United States Department of Justice.

NCLA Releases Video Depositions in Social Media Censorship Suit After Judge Orders Case to Be Heard

Retrieved on: 
Thursday, March 23, 2023
Vaccine, Learning, White House, Coercion, State, Supplement, Senior advisor, COVID-19, Immunity, Government, CDC, Injunction, Surgeon, District court, Mask, Complaint, Cybersecurity and Infrastructure Security Agency, FBI, NCLA, Federation, John Davis (U.S. district court judge), Big Tech, Memory, Social media, Pharmaceutical industry

Washington, D.C., March 23, 2023 (GLOBE NEWSWIRE) -- NCLA has released six video depositions taken in its federal lawsuit, State of Missouri, et al.

Key Points: 
  • Washington, D.C., March 23, 2023 (GLOBE NEWSWIRE) -- NCLA has released six video depositions taken in its federal lawsuit, State of Missouri, et al.
  • As revealed in Elvis Chan’s deposition, the FBI played a major role in working with Big Tech companies to censor speech.
  • Actions ranged from weekly meetings with social media companies to demanding takedowns of specific accounts and facilitating suppression of certain stories.
  • Now that the judge has allowed this case to proceed, we look forward to learning even more as the case enters the merits discovery phase.”

Lurking Beneath the Surface: Hidden Impacts of Pixel Tracking

Retrieved on: 
Saturday, March 18, 2023
Online, Dark, Security controls, Marketing, GoodRx, Markup, Privacy, Blog, Federal Trade Commission, JavaScript, Risk, Advertising, OPP, Title 21 CFR Part 11, Consumer, Milk, Acts 18, DuckDuckGo, CFR, Research, Name, Others, FTC, Online and offline, Pixel, Social media, Technology, Method, Disclosure, Health, Business, Feather, BCP, OGC, Thought, Fire sale, BetterHelp, Egg as food, Injunction, HTML, Data collection, Federal Trade Commission Act of 1914, Supermarket, Security, Targeted advertising, New York City Office of Technology and Innovation, Mobile phone, Television, Online shopping, Cryptocurrency, Dietary supplement, Typesetting, Hazardous waste, BC, Facebook, Industry

Both cases highlighted the use of third-party tracking pixels, which enable platforms to amass, analyze, and infer information about user activity.

Key Points: 
  • Both cases highlighted the use of third-party tracking pixels, which enable platforms to amass, analyze, and infer information about user activity.
  • Tracking pixels have evolved from tiny, pixel-sized images on web pages for tracking purposes to include a broad range of HTML and JavaScript embedded in web sites (and email).
  • [8] Companies who are interested in pixel tracking must first choose a pixel tracking provider.
  • One way to monetize pixel tracking is for companies to use the tracking data collected to improve the company's own marketing campaigns.
  • Traditional controls such as blocking third party cookies may not entirely prevent pixels from collecting and sharing information.
  • Pixels are widely considered an industry standard tool, but the GoodRx and BetterHelp examples show that they may collect sensitive data.
  • *Some pixel tracking methods ostensibly attempt to remove personal information but may in fact still leak enough information to identify an individual.

Enjoin Announces Addition to Leadership Team to Accelerate Market Expansion

Retrieved on: 
Tuesday, June 28, 2022
Digital technology, KLAS, First Look, Risk-adjusted return on capital, AMN, Justin, Workforce, Growth, CCS, History, CRO, Peder Wallenberg, Risk, Sales, Technology, CMI, Solution, Physician, MD, CVS Caremark, Multimedia, CCDS, Video game, Pharmaceutical industry, Nym, Injunction

COLLIERVILLE, Tenn., June 28, 2022 /PRNewswire/ -- Enjoin, a physician-directed mid-revenue cycle solutions provider, announced today expansion of its executive leadership team to include Peder Christensen as the company's Chief Revenue Officer (CRO). Peder will lead all aspects of the company's sales, business development, and strategic partnerships with a focus on growth in Enjoin's solutions portfolio and geographic markets.

Key Points: 
  • COLLIERVILLE, Tenn., June 28, 2022 /PRNewswire/ -- Enjoin , a physician-directed mid-revenue cycle solutions provider, announced today expansion of its executive leadership team to include Peder Christensen as the company's Chief Revenue Officer (CRO).
  • "This is an exciting time of growth for Enjoin and we are excited to have Peder join our team.
  • "In addition, his commitment to client satisfaction and building collaborative client partnerships complements Enjoin's well established reputation and history of long-term client relationships.
  • "I'm thrilled to be a part of Enjoin, especially now, given the market opportunity to deliver high value, quality solutions to support the mid-revenue cycle," said Peder.

Aerojet Rocketdyne Executive Chairman Warren Lichtenstein Comments on Court Victory with Finding that CEO Eileen Drake Acted Unlawfully

Retrieved on: 
Friday, June 17, 2022
Banking, Professional Services, Finance, SPLP, Climate change, Contract, Delaware Court of Chancery, Securities Exchange Act of 1934, COVID-19, Risk, SOFR, Environment, AJRD, Steel, Injunction, Investigation, Court, Company, Press release, Computershare, SBA, Pressure, Securities Act of 1933, Negotiation, Greenhouse, Investment, Aerojet Rocketdyne Holdings, Sale, SEC, Partnership, Legislation, Board, PPP, Federation, Delaware Court, Form 10-K, Lichtenstein, TRO, NYSE, Disclosure, Online gambling, Public relations, Management, Risk management, Aerojet

The Court found that Ms. Drake violated its Temporary Restraining Order (TRO), and then falsely testified to the contrary.

Key Points: 
  • The Court found that Ms. Drake violated its Temporary Restraining Order (TRO), and then falsely testified to the contrary.
  • For example, the Court wrote that Drake testified that Aerojet did not meaningfully facilitate the transfer of Aerojet shares into her personal Computershare account.
  • She claims that she did nothing more than ask for Aerojet employees to provide ministerial assistance in unlocking her Computershare password.
  • The Court found that Ms. Drake weaponized the internal investigation of Mr. Lichtenstein in order to impugn his credibility.

Enjoin Grows Leadership Team to Support Mid-Revenue Cycle Solution Expansion

Retrieved on: 
Tuesday, May 3, 2022
Health, CCDS, CCS, Justin, Physician, Partnership, Founder, The Advisory Board Company, CDI, Workforce, Leadership, MD, Multimedia, Conference, Growth, Risk, KLAS, Pharmaceutical industry, Medicine, Injunction

ORLANDO, Fla., May 3, 2022 /PRNewswire/ -- Enjoin, a physician-directed clinical documentation integrity (CDI) services provider, announces expansion of its executive leadership to include Justin C. Schmidt as the company's Co-Chief Executive Officer. Justin will work closely with current CEO James P. Fee, MD, CCS, CCDS to accelerate market-driven services for both clinical and financial strategic alignment. This powerful combination of leadership will help grow the Enjoin brand and clinical practicing physician experience to all mid revenue cycle functions in support of Enjoin's mission for better patient outcomes and physician alignment. The announcement was made during the opening session of ACDIS National Conference in Orlando.

Key Points: 
  • This powerful combination of leadership will help grow the Enjoin brand and clinical practicing physician experience to all mid revenue cycle functions in support of Enjoin's mission for better patient outcomes and physician alignment.
  • "We are excited to have Justin join our executive leadership team," says Garry L. Huff, M.D., President and Founder of Enjoin.
  • Together, Justin and Dr. Fee will partner in efforts to support the market need for growth of physician partnerships across all aspects of the mid revenue cycle."
  • He has held leadership positions notably President and co-founder of Peak Health Solutions and Head of Revenue Cycle Solutions for AMN Healthcare.